en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2021
vol. 96
 
Share:
Send email
Share:
abstract:
Case report

Successful treatment of infliximab-induced psoriasiform skin lesions despite biologic therapy intensification in a paediatric patient with Crohn’s disease and primary sclerosing cholangitis

Agata Wasilewska
1
,
Małgorzata Chmielowska-Trybek
1
,
Małgorzata Sładek
1

  1. Department of Paediatrics, Gastroenterology and Nutrition, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
Pediatr Pol 2021; 96 (2): 143–147
DOI: https://doi.org/10.5114/polp.2021.107400
Online publish date: 2021/07/01
View full text Get citation
 
PlumX metrics:
Therapy with infliximab (IFX), a tumour necrosis factor-α (TNF-α) inhibitor, has been demonstrated to be highly effective in several immune-mediated inflammatory diseases including Crohn’s disease (CD) and psoriasis, both in adult and paediatric patients. With the increasingly widespread use and longer follow-up of IFX, one unexpected adverse effect that has been reported is the occurrence of psoriasis-like lesions, mainly during the maintenance therapy. The present report was aimed at describing a new case of IFX-induced psoriasis-like lesions in a 17-year-old boy with CD and primary sclerosing cholangitis (PSC), which was successfully treated with topical agents, despite IFX therapy intensification due to loss of the clinical response.
keywords:

infliximab, Crohn’s disease, primary sclerosing cholangitis, paradoxical psoriasis, adverse effects